AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01723644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the clinical reassessment arm
Description: In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
Study NCT01723644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the procalcitonin arm
Description: In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
Study NCT06773442 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation Practices Group
Description: Evidence-Based Training Program:Develop a structured training program for rehabilitation professionals focusing on evidence-based shoulder rehabilitation practices.~Clinical Mentorship and Supervision:Implement a mentorship program where experienced rehabilitation professionals provide guidance and support to junior staff members.~Standardization of Rehabilitation Protocols:Review and standardize rehabilitation protocols for common shoulder conditions based on current evidence and best practices.~Patient-Centered Care Approach:Adopt a patient-centered approach to shoulder rehabilitation, emphasizing shared decision-making and individualized treatment plans Outcome Monitoring and Quality Improvement:Use standardized outcome measures to evaluate improvements in pain, function, range of motion, and patient satisfaction.
Study NCT06773442 — intervention group
Intervention type: OTHER
Intervention: Documentation Protocols Group
Description: Training and Education Program:Develop and implement a training program for rehabilitation professionals aimed at enhancing their knowledge and skills in shoulder rehabilitation practices and documentation protocols.~Standardization of Protocols:Review and update existing rehabilitation protocols to ensure alignment with current evidence-based guidelines and best practices.~Quality Assurance Measures:Establish a system for ongoing monitoring and evaluation of shoulder rehabilitation practices and documentation protocols.~Patient Education and Engagement:Develop educational materials and resources for patients undergoing shoulder rehabilitation to enhance their understanding of treatment goals, exercises, and self-management strategies.~Outcome Monitoring and Evaluation:Implement a system for monitoring and evaluating patient outcomes, including pain levels, range of motion, functional status, and satisfaction with rehabilitation services.
Study NCT02207946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT02207946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT02777528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Endovascular repair with the TBE Device
Study NCT02777528 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Revascularization Procedure
Description: Revascularization procedure of the great vessel
Study NCT01777763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg
Study NCT02595632 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03310307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: 50,000 IU
Study NCT03310307 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01777763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg
Study NCT03667001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50mg NANO-efavirenz
Description: OD
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg NANO-Lopinavir
Description: BID
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg NANO-Lopinavir
Description: BID
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg Ritonavir
Description: BID
Study NCT03667001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
Study NCT04444232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View an educational video
Study NCT04444232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT00945360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor)
Description: Letrozole at a dose of 2.5 mg/day for 8 weeks.
Study NCT03760484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg
Description: Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
Study NCT03760484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation (FMT)
Description: Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
Study NCT05302323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Disposable Drape
Description: Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300mg NANO-Efavirenz
Description: OD
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 600mg Sustiva
Description: OD
Study NCT05302323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reusable Drape
Description: Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
Study NCT00332956 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rFIV vaccine
Description: rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
Study NCT00332956 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine
Description: rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
Study NCT00332956 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine
Description: rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
Study NCT00332956 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine 160 mcg given on Study Days 0, 56, 182
Description: rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
Study NCT00721487 — intervention group
Intervention type: DRUG
Intervention: Fluconazole
Description: Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
Study NCT03926676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: grandio blocks
Description: nano hybrid composite blocks
Study NCT03926676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grandio blocks
Description: nano hybrid composite blocks
Study NCT03926676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emax
Description: ceramic blocks
Study NCT03926676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emax
Description: ceramic blocks
Study NCT01062360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine
Description: Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study NCT01062360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study NCT01062360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study NCT01062360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study NCT02168686 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-043
Description: Gene transfer vector administration
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg NANO-Efavirenz
Description: OD
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kaletra® (lopinavir 400mg/ritonavir 100mg)
Description: BID
Study NCT03394560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
Study NCT03394560 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High frequency repetitive transcranial magnetic stimulation
Description: Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
Study NCT04214847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve surgery
Description: The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
Study NCT04214847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve surgery
Description: The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
Study NCT03233932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LeuplinⓡInj
Description: Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
Study NCT03233932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841
Description: Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
Study NCT02245048 — intervention group
Intervention type: OTHER
Intervention: Carotid Intima-Media Thickness (CIMT)
Study NCT00578123 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
Study NCT02862314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT05145621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod 0.5 mg capsules- Test drug
Description: An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOPS1 DBS
Description: TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS1 DBS
Description: TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOPS2 DBS
Description: TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS2 DBS
Description: TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOPS3 DBS
Description: TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS3 DBS
Description: TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: +/- 200mg NANO-Lopinavir
Description: BID
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard DBS
Description: Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
Study NCT04390867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard DBS
Description: Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
Study NCT03592979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude: (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study NCT03592979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study NCT03120169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill endurance training
Description: n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
Study NCT03120169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cycling endurance training
Description: n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
Study NCT00669617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
Study NCT00669617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50/500 μg)
Description: Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
Study NCT00669617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Description: Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
Study NCT00669617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo to indacaterol delivered via SDDPI
Study NCT00669617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol/fluticasone
Description: Placebo to salmeterol/fluticasone delivered via MDDPI
Study NCT00669617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salbutamol
Description: Placebo to salbutamol delivered via MDDPI
Study NCT02977923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR distraction via Oculus Rift
Description: In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.